PT3634419T - Regime de dosagem compreendendo um antagonista da hormona de libertação de gonadotropina para tratar miomas uterinos e reduzir a perda de sangue menstrual - Google Patents
Regime de dosagem compreendendo um antagonista da hormona de libertação de gonadotropina para tratar miomas uterinos e reduzir a perda de sangue menstrualInfo
- Publication number
- PT3634419T PT3634419T PT187319769T PT18731976T PT3634419T PT 3634419 T PT3634419 T PT 3634419T PT 187319769 T PT187319769 T PT 187319769T PT 18731976 T PT18731976 T PT 18731976T PT 3634419 T PT3634419 T PT 3634419T
- Authority
- PT
- Portugal
- Prior art keywords
- gonadotropin
- releasing hormone
- blood loss
- menstrual blood
- dosing regimens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515232P | 2017-06-05 | 2017-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3634419T true PT3634419T (pt) | 2025-04-04 |
Family
ID=62636157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT187319769T PT3634419T (pt) | 2017-06-05 | 2018-06-05 | Regime de dosagem compreendendo um antagonista da hormona de libertação de gonadotropina para tratar miomas uterinos e reduzir a perda de sangue menstrual |
Country Status (18)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3384930A1 (en) | 2013-03-15 | 2018-10-10 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| MX2019014482A (es) | 2017-06-05 | 2020-08-17 | ObsEva SA | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. |
| KR20250117836A (ko) | 2017-06-05 | 2025-08-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| IL278082B2 (en) | 2018-04-19 | 2025-03-01 | Abbvie Inc | Methods of treating heavy menstrual bleeding |
| CA3107597A1 (en) * | 2018-08-01 | 2020-02-06 | Abbvie Inc. | Dosing regimens for elagolix |
| EP3873465B1 (en) | 2018-10-29 | 2025-01-15 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| EP3876943A2 (en) * | 2018-11-07 | 2021-09-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| US20220305017A1 (en) * | 2019-08-08 | 2022-09-29 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN114364384A (zh) * | 2019-08-08 | 2022-04-15 | 奥布赛瓦股份公司 | 用于治疗雌激素依赖性病症的GnRH拮抗剂 |
| KR20210155350A (ko) | 2020-06-15 | 2021-12-22 | 한상왕 | 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| KR102738115B1 (ko) | 2024-03-25 | 2024-12-05 | 한상왕 | 자궁근종 예방, 개선 또는 치료용 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109171B2 (en) * | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| BRPI0617436B8 (pt) | 2005-10-19 | 2021-05-25 | Kissei Pharmaceutical | derivado heterocíclico fundido, composição farmacêutica compreendendo o mesmo e usos do dito derivado na prevenção ou tratamento de doença dependente de hormônio sexual e na regulação da reprodução, contracepção ou indução de ovulação |
| BR112012020110B1 (pt) | 2010-02-10 | 2021-06-08 | Kissei Pharmaceutical Co., Ltd. | composto derivado heterocíclico fusionado, composição farmacêutica que compreende o mesmo e uso terapêutico do dito composto |
| WO2014042176A1 (ja) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| EP3384930A1 (en) * | 2013-03-15 | 2018-10-10 | AbbVie Inc. | Compositions for use in treating heavy menstrual bleeding |
| CA3025760A1 (en) | 2016-08-08 | 2018-02-15 | Kissei Pharmaceutical Co., Ltd. | Usage and dosage of therapeutic agents for endometriosis |
| DK3518933T4 (da) | 2016-09-30 | 2025-04-22 | Takeda Pharmaceuticals Co | Fremgangsmåder til behandling af uterusfibromer og endometriose |
| MX2019014482A (es) | 2017-06-05 | 2020-08-17 | ObsEva SA | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. |
| KR20250117836A (ko) | 2017-06-05 | 2025-08-05 | 깃세이 야쿠힌 고교 가부시키가이샤 | 자궁내막증의 치료를 위한 고나도트로핀 방출 호르몬 길항제 투약 요법 |
| EP3876943A2 (en) | 2018-11-07 | 2021-09-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
-
2018
- 2018-06-05 MX MX2019014482A patent/MX2019014482A/es unknown
- 2018-06-05 JP JP2019566909A patent/JP7292566B2/ja active Active
- 2018-06-05 US US16/619,702 patent/US11759464B2/en active Active
- 2018-06-05 WO PCT/EP2018/064767 patent/WO2018224497A1/en not_active Ceased
- 2018-06-05 KR KR1020197038980A patent/KR102884301B1/ko active Active
- 2018-06-05 CN CN201880050807.2A patent/CN110996957A/zh active Pending
- 2018-06-05 ES ES18731976T patent/ES3018358T3/es active Active
- 2018-06-05 HR HRP20250390TT patent/HRP20250390T1/hr unknown
- 2018-06-05 SG SG11201911599XA patent/SG11201911599XA/en unknown
- 2018-06-05 PT PT187319769T patent/PT3634419T/pt unknown
- 2018-06-05 DK DK18731976.9T patent/DK3634419T3/da active
- 2018-06-05 HU HUE18731976A patent/HUE070907T2/hu unknown
- 2018-06-05 FI FIEP18731976.9T patent/FI3634419T3/fi active
- 2018-06-05 MX MX2023013582A patent/MX2023013582A/es unknown
- 2018-06-05 CA CA3066188A patent/CA3066188A1/en active Pending
- 2018-06-05 AU AU2018280741A patent/AU2018280741B2/en active Active
- 2018-06-05 EA EA201992812A patent/EA201992812A1/ru unknown
- 2018-06-05 PL PL18731976.9T patent/PL3634419T3/pl unknown
- 2018-06-05 EP EP24221894.9A patent/EP4509173A3/en active Pending
- 2018-06-05 EP EP18731976.9A patent/EP3634419B1/en active Active
-
2023
- 2023-03-20 JP JP2023043718A patent/JP7485815B2/ja active Active
- 2023-09-11 US US18/244,773 patent/US20240000785A1/en active Pending
-
2024
- 2024-03-14 AU AU2024201694A patent/AU2024201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634419B1 (en) | 2025-01-29 |
| KR102884301B1 (ko) | 2025-11-11 |
| EP3634419A1 (en) | 2020-04-15 |
| PL3634419T3 (pl) | 2025-06-09 |
| HUE070907T2 (hu) | 2025-07-28 |
| DK3634419T3 (da) | 2025-03-31 |
| US20240000785A1 (en) | 2024-01-04 |
| KR20200024797A (ko) | 2020-03-09 |
| CA3066188A1 (en) | 2018-12-13 |
| ES3018358T3 (es) | 2025-05-16 |
| MX2023013582A (es) | 2024-04-16 |
| US11759464B2 (en) | 2023-09-19 |
| MX2019014482A (es) | 2020-08-17 |
| JP7485815B2 (ja) | 2024-05-16 |
| JP2023078315A (ja) | 2023-06-06 |
| AU2018280741A1 (en) | 2020-01-30 |
| US20200179390A1 (en) | 2020-06-11 |
| AU2024201694A1 (en) | 2024-04-04 |
| EP4509173A2 (en) | 2025-02-19 |
| FI3634419T3 (fi) | 2025-05-02 |
| EP4509173A3 (en) | 2025-06-04 |
| SG11201911599XA (en) | 2020-01-30 |
| HRP20250390T1 (hr) | 2025-05-23 |
| JP2020522525A (ja) | 2020-07-30 |
| CN110996957A (zh) | 2020-04-10 |
| AU2018280741B2 (en) | 2023-12-21 |
| WO2018224497A1 (en) | 2018-12-13 |
| EA201992812A1 (ru) | 2020-05-21 |
| JP7292566B2 (ja) | 2023-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201911599XA (en) | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss | |
| IL300580B2 (en) | Methods for treating uterine fibroids and endometrial disease | |
| SG11201911598WA (en) | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | |
| IL273031A (en) | Combined treatment of lasmiditan and a CGRP antagonist for use in the treatment of migraine | |
| PT3270957T (pt) | Novo complexo que compreende um péptido de penetração celular, uma carga e um agonista peptídico de tlr para o tratamento de glioblastoma | |
| IL268376A (en) | Compositions for long-term release of gonadotropin-releasing hormone (GHRH) inhibitors and methods of their use | |
| IL280592A (en) | Devices and methods for vaginal treatments | |
| ZA201704958B (en) | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | |
| ZA201900777B (en) | Usage and dosage of therapeutic agents for endometriosis | |
| IL272864A (en) | A therapeutic agent containing an IL-33 antagonist for the treatment of endometriosis | |
| IL277238A (en) | Modified oligonucleotides for use in the treatment of tauopathy | |
| IL275340A (en) | Peptides and other active compounds to treat pain and increase pain sensitivity | |
| IL248621B (en) | Formulations and methods for vaginal administration of antiprogestins | |
| PH12017502100A1 (en) | Selective progesterone receptor modulator (sprm) regimen | |
| EP3258858A4 (en) | IMPROVED BELT TOLERANT FOR THE TREATMENT OF HEMORRHOIDS AND LOADING DEVICE | |
| PT3648761T (pt) | Telmisartan para a profilaxia ou tratamento de hipertensão em gatos | |
| EP2985024A4 (en) | THERAPEUTIC FOR SYSTEMIC BONE DISEASES AND USE THEREOF | |
| IL273863A (en) | Hemorrhoid treatment device | |
| IL264243B (en) | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage | |
| SG11202012889QA (en) | Dosing regimens for treating hypoxia-associated tissue damage | |
| HK40027582A (en) | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | |
| IL240710A0 (en) | Administration of sdf-1 to treat ischemic tissue | |
| HK40050740A (en) | Dosing regimens for treating hypoxia-associated tissue damage |